NovaBridge Biosciences

NASDAQ:NBP

Biotechnology

Healthcare
$0.90 -4.78%

-$0.07 today

Market cap
$104.10M
Beta
1.48
P/E (TTM)
-25.5
EPS (TTM)
-$0.40
52W Low $1.46High $6.79

Volume 0.87M

Average 0.90M

NBP Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

NovaBridge BiosciencesNASDAQ: NBP

Investing Cash Flow · Q4 FY2025 · quarter ended Dec 2025

Investing cash flow outflow grows to $0

Q4 FY2025 investing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month investing cash flow was -$360.38K. Over 3 fiscal years it compounded at -38.8% a year.

Context

  • Investing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$90.09K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$0+100.0% QoQ
Last fiscal yearDec 2025
$104.97M+110.6% YoY
LTMSep 2025
-$360.38K— YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+110.6%——
3-year CAGR-38.8%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

Mixed currencies · from the cash flow

Latest · FY2025
104.97M USD
Year-over-year change
—

Investing Cash Flow vs competitors

How NBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of -38.8% compares with a peer median of +35.0%.
NBP Competitors
Investing Cash Flow for NBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$179.25M USD+363.9%——
ALTAltimmune, Inc.LTM Mar 2026$131.06M USD-2272.1%+21.8%364061.1%
ANNXAnnexon, Inc.LTM Mar 2026$119.49M USD+372.3%+48.2%—
ENGNenGene Holdings Inc.LTM Apr 2026$60.78M USD-68.4%+447.7%—
AURAAura Biosciences, Inc.LTM Mar 2026$60.68M USD-32.0%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$42.41M USD———
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$20.59M USD—-38.8%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$11.37M USD-203.5%——
DSGNDesign Therapeutics, Inc.LTM Mar 2026$7.45M USD-76.1%——
NBPNovaBridge BiosciencesLTM Sep 2025CN¥360.38K CNY—-38.8%—
GALTGalectin Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding NBP) —-68.4%+35.0%364061.1%

Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CNY
FY2022
Dec 2022 · CNY
FY2023
Dec 2023 · CNY
FY2024
Dec 2024 · CNY
FY2025
Dec 2025 · USD
Net Income(2.33B)(2.51B)(208.18M)(362.72M)(88.34M)
Depreciation & Amortization34.14M63.82M1.06M7.14M856K
Deferred Income Tax00000
Stock-Based Compensation608.61M357.15M10.26M(14.23M)5.97M
Change in Working Capital394.52M552.06M(37.2M)(20.52M)17.07M
Accounts Receivables97.42M33.08M000
Inventory(27.24M)27.24M000
Accounts Payables107.85M0000
Other Working Capital216.49M491.75M(37.2M)(20.52M)17.07M
Other Non-Cash Items321.18M431.48M161.2M5.9M43.84M
Operating Cash Flow(973.09M)(1.1B)(72.85M)(384.42M)(20.6M)
Capital Expenditures(29.93M)(45.83M)(164.35K)(350.34K)(7K)
Acquisitions (Net)(6M)0000
Purchases of Investments(10.17B)(7.41B)0(1.79B)(49.96M)
Sales of Investments9.48B7.91B0801.66M154.89M
Other Investing Activities026K(107.47M)452.53K47K
Investing Cash Flow(727.21M)458.38M(107.63M)(992.42M)104.97M
Debt Repayment02.75M000
Common Stock Issued000061.91M
Common Stock Repurchased0(3.08M)(8.66M)(2.45M)0
Dividends Paid00000
Other Financing Activities593.92M60.86M407.88K0(4.19M)
Financing Cash Flow593.92M42.36M(8.25M)(2.44M)57.73M
Effect of Forex Changes(128.77M)389.2M36.89M(327.04M)276K
Net Change in Cash(1.24B)(212.86M)(151.58M)(1.71B)142.37M
Free Cash Flow(1B)(1.15B)(73.02M)(384.77M)(20.6M)

NovaBridge Biosciences

NASDAQ:NBP

Intrinsic Alpha fair value

Locked

Current Price

$0.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.